Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial to test its experimental therapy MTX-463 in people with idiopathic pulmonary fibrosis (IPF). The company has entered into a global ...

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.